| Combination of | |
|---|---|
| Lamivudine | nucleoside reverse transcriptase inhibitor |
| Nevirapine | non-nucleoside reverse transcriptase inhibitor |
| Zidovudine | nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Duovir-N, Zidovex-LN, others[1] |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[2] It contains lamivudine, nevirapine, and zidovudine.[2] It is either used by itself or along with other antiretrovirals.[2] It is a recommended treatment in those who are pregnant.[2] It is taken by mouth twice a day.[2]
The medication is generally well tolerated.[1] Side effects are those of the underlying medications.[2] This includes rash, pancreatitis, low white blood cell levels, and muscle pain.[1] Use is not recommended in those with significant liver problems.[1] Use in pregnancy and breastfeeding appear to be safe.[1] The combination tablet is typically not appropriate for children.[2]
It is on the World Health Organization's List of Essential Medicines.[3] The combination is not commercially available in the United States as of 2018.[4]
See also
References
- 1 2 3 4 5 "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
- 1 2 3 4 5 6 7 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.